• ipharmaservices

Lundbeck acquired Abide Therapeutics and their lead compound ABX-1431

Updated: Jun 3, 2019

Lundbeck has completed the acquisition of US-based biotech company Abide Therapeutics and the lead compound ABX-1431.



On May 6th, 2019 Lundbeck announced that it was acquiring Abide Therapeutics. Abide Therapeutics is currently working the serine hydrolases; the acquisition helps

Lundbeck to work on new classes of drugs for a range of therapeutic activities.


Also, Lundbeck gets the advanced compound ABX-1431 first-in-class MAG Lipase inhibitor used for the treatment of Tourette Syndrome and neuropathic pain.

Please donate to support iPharmaCenter. Click on donate button in header to support us. Thank you

©2020 by ipharmaservices